Introduction to the Alliance Between Processa and Intact Therapeutics
HANOVER, Md. — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has established a significant binding term sheet with Intact Therapeutics, Inc. This collaboration gives Intact an exclusive option to license PCS12852, a promising new treatment aimed at addressing gastroparesis and other gastrointestinal motility disorders.
Financial Details of the Agreement
As part of this agreement, Processa stands to gain substantial financial support, including an upfront option exercise fee of $2.5 million. Additionally, the company can earn up to $20 million in development and regulatory milestone payments, alongside a staggering $432.5 million based on future commercial milestones linked to product sales. A noteworthy aspect of this partnership is that Intact will also provide Processa with a double-digit royalty on global net sales, barring South Korea.
Value Proposition of PCS12852
PCS12852 is designed as a best-in-class 5-HT4 receptor agonist. In early clinical trials, it has shown a strong safety profile and efficacy in treating diabetic gastroparesis, which is a condition that severely disrupts gastric motility. This treatment stands out in a market plagued by limited options and represents a significant stride towards improving the lives of those suffering from gastrointestinal disorders.
Expert Insights
George Ng, CEO of Processa, shared his enthusiasm about this partnership, emphasizing how it allows the company to unlock the potential of its non-oncology assets while maintaining focus on advancing next-generation cancer therapies.
Ravi Pamnani, CEO of Intact Therapeutics, echoed this sentiment, highlighting the company's mission to bridge existing gaps in gastrointestinal treatments, not just for managing conditions but also for enhancing the overall quality of life for patients.
The Importance of Innovative Therapies
The collaboration indicates a strong commitment to addressing unmet clinical needs within the GI space. The safety and efficacy data surrounding PCS12852 solidify its status as a viable candidate that could significantly improve gastric motility in patients suffering from gi disorders. Lorin K. Johnson, Ph.D., a Board Member and Scientific Advisor to Intact Therapeutics, believes that the partnership will yield mutual benefits, enhancing the therapeutic landscape for gastrointestinal disorders.
What Lies Ahead for Processa and Intact Therapeutics?
The license agreement will take effect once definitive agreements are finalized and all closing conditions are met, which includes amending the license with Processa's current licensor. This proactive alignment suggests robust planning for future successes in the market.
About Intact Therapeutics, Inc.
Intact Therapeutics is at the forefront of pioneering new therapies for gastrointestinal diseases. With a foundation rooted in cutting-edge research from Stanford University, the company is advancing innovative products utilizing proprietary thermal hydrogel technology. Their unique approach promises to expand treatment options in the field significantly.
About Processa Pharmaceuticals, Inc.
Processa is dedicated to developing next-generation cancer (NGC) therapies, which enhance the safety and efficacy of existing FDA-approved oncology substances. With a focus on modifying drug metabolism, they aim to create effective treatment plans while ensuring a high level of tolerability for patients.
Frequently Asked Questions
What is the focus of the partnership between Processa and Intact Therapeutics?
The partnership aims to advance PCS12852, a treatment for gastroparesis and gastrointestinal motility disorders.
What financial benefits does Processa Pharmaceuticals expect from this agreement?
Processa expects to receive a $2.5 million option exercise fee, milestones payments of up to $20 million, and $432.5 million in commercial milestone payments based on product sales.
What is PCS12852?
PCS12852 is a selective 5-HT4 receptor agonist designed to improve gastric motility, particularly for patients suffering from diabetic gastroparesis.
How does Intact Therapeutics plan to utilize PCS12852?
Intact plans to integrate PCS12852 into its GI portfolio, aiming to enhance the quality of life for patients with existing GI disorders.
What are the future plans for this collaboration?
The license agreement will begin after all closing conditions are satisfied, allowing both companies to further their developments toward commercialization.
